ArticleInternational journal of chronic obstructive pulmonary disease2026
Development and Real-World Evaluation of an Interpretable Machine Learning Framework for Predicting COPD-Related Healthcare Costs.
Article in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) imposes a substantial economic burden. While machine learning (ML) enables data-driven cost prediction, real-world benchmarking comparing algorithms, data-splitting strategies, and feature optimization on continuous, skewed healthcare expenditures remains limited. Objective: To develop an interpretable ML framework for predicting annual COPD-related healthcare expenditures, assessing the impact of algorithm selection, train-test split ratios, and feature optimization. Methods: We analyzed a retrospective cohort of 396 COPD patients from a Taiwanese medical center. Annual healthcare costs were log-transformed and standardized due to extreme skewness. Five ML regression algorithms were benchmarked across four train-test split ratios. Recursive feature elimination with cross-validation (RFECV) applied within training sets identified an optimal predictor subset. Model interpretability was assessed using SHapley Additive exPlanations (SHAP). Performance was evaluated using R-squared (R Results: The 80:20 split yielded the most stable generalization performance. Gradient Boosting achieved the highest accuracy (test R Conclusion: Gradient Boosting provides robust predictive performance for COPD healthcare costs. A parsimonious six-feature set enhances interpretability without compromising accuracy. This explainable ML framework supports cost-aware healthcare management, pending future multi-center validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.